Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.

Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV
Clin Infect Dis. 2008 47 (3): 421-4

PMID: 18558886 · PMCID: PMC2586907 · DOI:10.1086/589867

Using standard and ultrasensitive techniques, we detected nonnucleoside reverse-transcriptase inhibitor-associated resistance mutations in 11 (20%) of 54 subjects who discontinued virologically suppressive nonnucleoside reverse-transcriptase inhibitor-containing antiretroviral therapy. Resistance was detected in 45% and 14% of subjects with a baseline human immunodeficiency virus type 1 RNA level of 51-400 copies/mL and

MeSH Terms (11)

Adult Drug Administration Schedule Drug Resistance, Viral Female HIV-1 HIV Infections Humans Male Mutation Reverse Transcriptase Inhibitors Viral Load

Connections (1)

This publication is referenced by other Labnodes entities: